Oncolix, Inc. - Clinical-stage Biotechnology Company Developing Prolanta™ for the Treatment of Ovarian, Uterine, Breast and Other Cancers

Oncolix (OTCQB: ONCX) is a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian, uterine, breast and other cancers, according to the company’s website (see here: www.oncolixbio.com). SNNLive spoke with Michael Redman, President and CEO of Oncolix, Inc., at the LD Micro Invitational 2018 in Bel Air, CA, and they discuss the following topics:

- Overview and history of Oncolix, Inc.

- Prolanta™, its applications and how it works

- Size of patient population of Ovarian Cancer

- Today’s standard-of-care and company’s differentiation factors

- Competitive advantage

- Mr. Redman’s background

- Growth drivers

For more information about Oncolix, Inc., please visit: www.oncolixbio.com

The interview may contain forward-looking statements about Oncolix, Inc. See Oncolix, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

Please read our full disclosure here.